Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Added 117 days ago (19.01.2022)
Authors: Frédéric Vanhoutte; Wen Liu; Richard T Wiedmann; Liesbeth Haspeslagh; Xin Cao; Keith Boundy; Antonios Aliprantis; Michelle Davila; Jonathan Hartzel; Jianing Li; Mac McGuire; Katrin Ramsauer; Yvonne Tomberger; Roland Tschismarov; Deborah D Brown; Weifeng Xu; Jeffrey R Sachs; Kevin Russell; S Aubrey Stoch; Eseng Lai
Journal: EBioMedicine
Read article